Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib plus Cetuximab in EGFR Exon 20 Insertion Positive NSCLC
NCT03727724Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2018
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib and cetuximab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Disease Control Rate at 18 weeks. Started Dec 2018; status: completed.
02
Drugs
afatinibcetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03727724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727724.